Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

Kazumasa Komura · Teruo Inamoto · Tomoaki Takai · Taizo Uchimoto ·
Kenkichi Saito · Naoki Tanda · Junko Kono · Koichiro Minami ·
Hirohumi Uehara · Yutaka Fujisue · Kiyoshi Takahara · Hajime Hirano ·
Hayahito Nomi · Toshikazu Watsuji · Satoshi Kiyama · Haruhito Azuma

Received: 11 June 2013 / Accepted: 14 November 2013 / Published online: 23 November 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract

Purpose To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate® for patients with localized prostate cancer.

Methods Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.

Results A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D’Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cut-off = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, \( p < 0.001 \)) and D’amico risk groups [HR = 3.132 (95 % CI 1.251–6.389), \( p = 0.033 \)] were the predictor for failure in single-session HIFU.

Conclusions Single-session HIFU treatment using the Sonablate® seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.

Keywords HIFU · Localized prostate cancer · Single-session treatment · Outcome

Introduction

Prostate cancer is the most common cancer and leading cause of cancer death in men. Now varying treatment options are available for patients with localized prostate cancer. Radiotherapy (RT) with external beam radiation (EBRT) or brachytherapy is more widely used in the treatment of men aged over 65 years and seems to be the most famous less invasive therapy [1]. High-intensity focused ultrasound (HIFU), which is a non-surgical, minimally invasive treatment option using ablative technology, was developed in the 1990s and is now becoming an alternative to radiation therapy [2]. To date, durable cancer control outcomes of HIFU treatment have been reported with high volume cohort [3, 4], which were comparable to the other modalities such as EBRT [5]. Blana et al. investigated the biochemical events that best predicted clinical failure for patients treated with HIFU which derived Stuttgart definition; reaching a threshold of prostate-specific antigen (PSA) nadir level +1.2 ng/ml [6]. This definition is now becoming a widespread biochemical indicator for patients after HIFU in the recent studies, even though being more strict criteria compared with Phoenix definition; PSA nadir level +2.0 ng/ml for patients treated.
with EBRT [7]. Nevertheless, the role of HIFU as primary therapy for patients with prostate cancer is still controversial. In particular, repeated administrations of HIFU after positive follow-up biopsy, which is explained as new sessions of HIFU, potentially make the assessment of treatment efficacy difficult. Data reported so far a mixing result of single session and multiple sessions. Thus, it is clinically meaningful to evaluate the single-session HIFU treatment outcome. Recently, several reports that assessed clinically meaningful to evaluate the single-session HIFU result of single session and multiple sessions. Thus, it is difficult. Data reported so far a mixing result of single session and multiple sessions. Thus, it is clinically meaningful to evaluate the single-session HIFU treatment outcome. Recently, several reports that assessed treatment outcome for the single-session HIFU using the Ablatherm® have been reported [8, 9]; however, there is no available reports using the Sonablate® device. In this report, we first focused on the treatment outcome of single-session HIFU using the Sonablate® and clarified predictor for treatment failure after single-session HIFU treatment.

Materials and methods

Equipment

All patients were treated with the Sonablate® HIFU device (Focus Surgery, Indianapolis, IN, USA). The transrectal HIFU probe uses double transducer technology with low-energy ultrasound (4 MHz) for real-time imaging of the prostate and delivery of high-energy ablative pulses (site intensity 1,300–2,200 W/cm²).

Patients

The inclusion criteria for treatment in our institution were as follows: clinical stage T1-T2N0M0 biopsy-proven localized prostate cancer, prostate volume at diagnosis ≤50 ml, and no previous treatment for prostate cancer with curative intent. All patients were followed at least 24 months. This study was approved by the local institutional review board. Between 2004 and 2008, 180 consecutive patients undergoing HIFU at our institution were enrolled into a database. We analyzed the data of 171 patients who underwent single-session HIFU as the primary therapy with curative intent, excluding the data of 9 patients who were treated for salvage.

Pre-HIFU treatment protocol

Patients were offered neoadjuvant hormonal ablation (NHA) to reduce the prostatic volume and facilitate delivery of high-energy ablative pulses throughout the prostate when the initial size of the prostate was >35 ml. Any hormonal therapy was discontinued at the time of the HIFU. The prostatic volume was evaluated again immediately before HIFU. Transurethral resection of the prostate (TURP) was performed before HIFU to resect calcifications within the prostate, which would disable ablative pulses from reaching the targeted focus.

Follow-up

The follow-up examinations included digital rectal examinations (DRE), and PSA measurement every month during the first 6 months after treatment and every 3 months thereafter. A follow-up control octant biopsy was recommended to all patients 3–6 months after the treatment, and was also performed forcibly to all patients not achieved PSA level of 1.0 ng/ml at 6 months after the HIFU. Biochemical failure was defined according to the Stuttgart definition (a rise of 1.2 ng/ml or more above the nadir PSA) [6], which was generated for patients treated only with HIFU, and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA) [7], derived from the experience with EBRT. Disease-free survival rate (DFSR) was evaluated using the definition for disease failure, which was defined according to the Phoenix criteria: a rise of 2 ng/ml or more above the nadir PSA (biochemical failure), positive follow-up biopsy, or the administration of salvage treatment including second session of HIFU. In the present study, no patient received adjuvant hormonal therapy or any other salvage therapy including second-session HIFU treatment before the diagnosis of biochemical failure and positive follow-up biopsy. Therefore, disease failure was simply defined as PSA nadir +2 ng/ml or positive follow-up biopsy. We applied the two risk classification (i.e., D’Amico risk groups [10] and National Comprehensive Cancer Network (NCCN) risk groups [11]) to compare the treatment outcome with previous studies.

Statistical analysis

Continuous parametric variables were reported as the mean value ± standard deviation (SD). Continuous nonparametric variables were presented as the median value and interquartile range (IQR). The unpaired t test and the Mann–Whitney U test were used for quantitative parametric and nonparametric variables, respectively. Chi-square tests were conducted to assess the differences of the distributions between the clinicopathological parameters. The log-rank test was used to compare the curves based on Kaplan–Meier models. A multivariate Cox proportional hazards regression model was used to estimate the prognostic relevance of clinicopathological variables. Associations were regarded as significant if p < 0.05, and all p values were two-sided. All data were analyzed with the use of the Statistical Package for the Social Sciences software, version 12.0 (SPSS Inc, Chicago, IL).

Results

Patients’ characteristics

Table 1 summarizes the clinical and pathologic characteristics of 171 patients included in the analysis.
The overall and cancer-specific survival rates at 5 years were 98.8 and 100 %. The metastasis-free survival rate at 5 years was 99.4 %.

Biochemical and disease-free survival

Table 2 summarizes biochemical-free survival rates at 3 and 5 year. Stuttgart definition and Phoenix definition are utilized. Patients were stratified according to risk groups including D’Amico and NCCN. There was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively.

Additional subgroup analyses were conducted, using Phoenix definition (nadir +2 ng/ml) based on preoperative variables including prostatic volume immediately before HIFU (cutoff of 20 ml), TURP before HIFU and preoperative NHA (Fig. 1). None of them showed significant differences, while there was a tendency that administration of the TURP before HIFU favorably affected cancer control after HIFU, but this tendency did not achieve statistical significance.

Clinical outcomes

Control biopsy was performed in 103 (60.2 %) patients with 6.5 months of median duration to biopsy with 80.6 % (83/103) of negative biopsy rate. Of 103 patients, 91 (88.3 %) patients achieving PSA threshold level of 1.0 ng/ml were the candidates to undergo follow-up biopsy with 91.2 % (83/91) of negative biopsy rate, whereas all the remaining 11.7 % (12/103) patients not achieving the PSA level of 1.0 ng/ml at 6 months after HIFU had positive follow-up biopsy. Of the all of patients who had negative biopsy, 15.7 % (13/83) patients eventually experienced biochemical relapse for Phoenix definition. A total of 44 (25.7 %) patients (7, 9, and 28 patients for low, intermediate, and high D’amico risk group, respectively) were diagnosed as disease failure with Phoenix definition (nadir +2 ng/ml) in 24 patients and positive follow-up biopsy in 20 patients. Of those, a new HIFU session was offered as salvage therapy in 29.5 % (13/44) patients, hormone deprivation in 47.7 % (21/44) patients, and EBRT in 22.7 % (10/44) patients, respectively (Figs. 2, 3).

PSA nadir value after HIFU

Median nadir PSA was 0.03 ng/ml (IQR 0.01–0.30) with median time to PSA nadir of 2.5 months (IQR 1.0–3.0). Seventy-six patients (44.4 %) were offered administration of NHA, which would affect the course of PSA value after HIFU. Therefore, we stratified the patients according to the administration of NHA, in which the median nadir PSA level in patients offered NHA was significantly lower than those in patients not offered NHA (0.01 and 0.09 ng/ml, respectively) ($p = <0.001$) and median time to PSA nadir was also significantly shorter in the cohort offered NHA (2.0 months) compared with those not offered NHA (3.0 months) ($p = <0.001$). For the overall cohort, 120 (70.2 %) patients achieved PSA nadir level of ≤0.2 ng/ml, whereas the administration of NHA significantly contributed to achievement of PSA nadir level of ≤0.2 ng/ml ($p = <0.001$).

Predictive values for biochemical failure

On Cox regression analysis including pre-treatment PSA value, Gleason score, PSA nadir level, clinical T stage, and

| Table 1 | Patient population (n = 171) |
|---------|---------------------------|
| Median follow-up [mo] (IQR) | 43 (30–55) |
| Mean ± SD age | 68.3 ± 7.0 |
| Median PSA [ng/ml] (IQR) | 7.7 (5.8–12.6) |
| Mean ± SD prostatic volume [ml] | 20.1 ± 7.6 |
| Clinical stage (%) |  |
| cT1c | 47 (27.5) |
| cT2a | 51 (29.8) |
| cT2b | 40 (23.4) |
| cT2c | 33 (19.3) |
| Gleason score (%) |  |
| 5 or less | 9 (5.3) |
| 6 | 83 (48.5) |
| 7 | 37 (21.6) |
| Greater than 7 | 42 (24.6) |
| D’amico risk groups (%) |  |
| Low risk | 52 (30.4) |
| Intermediate risk | 47 (27.5) |
| High risk | 72 (42.1) |
| NCCN risk groups (%) |  |
| Low risk | 52 (30.4) |
| Intermediate risk | 66 (38.6) |
| High risk | 53 (31.0) |
| NHA (%) |  |
| No | 95 (55.6) |
| Yes | 76 (44.4) |
| Median duration of NHA [month] (IQR) | 3 (3–5.75) |
| TUR before HIFU (%) |  |
| No | 115 (67.3) |
| Yes | 56 (32.7) |

SD standard deviation, PSA prostate-specific antigen, IQR interquartile ranges, NCCN National Comprehensive Cancer Network, NHA neoadjuvant hormonal ablation, HIFU high-intensity focussed ultrasound, TUR transurethral resection.
Table 2 BFS and DFS probability in 171 patients after HIFU according to risk groups

| Variables          | Mean ± SE BFS probability | Mean ± SE DFS probability |
|--------------------|---------------------------|---------------------------|
|                    | Stuttgart definition      | Phoenix definition        |                     |
| No. of patients at risk | 63 12                     | 68 11                     | 67 11               |
| All cohort         | 0.72 ± 0.04 0.62 ± 0.05   | 0.77 ± 0.04 0.69 ± 0.05   | 0.73 ± 0.03 0.63 ± 0.05 |
| D’amico risk groups |                           |                           |                     |
| Low                | 0.85 ± 0.05 0.76 ± 0.08   | 0.85 ± 0.05 0.85 ± 0.05   | 0.81 ± 0.06 0.79 ± 0.07 |
| Intermediate       | 0.73 ± 0.08 0.68 ± 0.09   | 0.82 ± 0.07 0.73 ± 0.09   | 0.78 ± 0.07 0.72 ± 0.09 0.528 |
| Low + Intermediate | 0.80 ± 0.04 0.72 ± 0.06   | 0.83 ± 0.02 0.80 ± 0.05   | 0.80 ± 0.03 0.76 ± 0.05 0.528 |
| High               | 0.59 ± 0.06 0.48 ± 0.08   | 0.68 ± 0.06 0.51 ± 0.08   | <0.001 0.60 ± 0.06 0.47 ± 0.08 <0.001 |
| NCCN risk groups   |                           |                           |                     |
| Low                | 0.85 ± 0.05 0.76 ± 0.07   | 0.85 ± 0.05 0.85 ± 0.05   | 0.81 ± 0.06 0.79 ± 0.07 |
| Intermediate       | 0.70 ± 0.06 0.66 ± 0.06   | 0.78 ± 0.06 0.69 ± 0.08   | 0.71 ± 0.07 0.63 ± 0.08 0.102 |
| Low + Intermediate | 0.77 ± 0.04 0.70 ± 0.05   | 0.81 ± 0.04 0.77 ± 0.05   | 0.76 ± 0.04 0.71 ± 0.05 0.102 |
| High               | 0.59 ± 0.08 0.43 ± 0.09   | 0.67 ± 0.07 0.48 ± 0.10   | 0.002 0.63 ± 0.07 0.46 ± 0.09 0.007 |

BFS biochemical failure-free survival, DFS disease-free survival, HIFU high-intensity focussed ultrasound, SE standard error, NCCN National Comprehensive Cancer Network

Fig. 1 Kaplan–Meier curves of biochemical failure-free survival using Phoenix definition (nadir +2 ng/ml) based on the preoperative variables: a prostatic volume immediately before HIFU (cutoff of 20 ml), b preoperative NHA, and c TURP before HIFU
D’amico risk groups, the predictors for biochemical failure based on the Stuttgart definition after single session were PSA nadir >0.2 ng/ml (HR = 9.472 [95% CI 4.527–19.820], p < 0.001) and D’amico risk groups (HR = 3.132 [95% CI 1.251–6.389], p = 0.033).

Discussion

In the present study, we investigated the utility of the HIFU device as a primary therapy focused on single-session treatment for the localized prostate cancer. Follow-up monitoring on biochemical relapse for patients treated with HIFU has been conducted applying various definitions which had adaptation for radiation therapy and radical prostatectomy [7, 12–15]. Thus, to obtain integrity of treatment outcomes of HIFU treatment when comparing with previous published studies, we demonstrated the cancer control outcomes applying both biochemical definition including Stuttgart definition, which was derived from the previous studies focused on HIFU, and Phoenix definition, and stratified patients into two risk category including D’amico risk groups and NCCN risk groups.

Pinthus et al. [9] investigated oncological outcomes of single-session HIFU treatment using the Ablatherm® for 402 patients who have not undergone neither NHA nor preoperative TURP, in which they founded that patients with a prostate volume of ≤30 ml had significantly higher BCR-free rate for Stuttgart definition (at 4 years 72 % for a prostate volume ≤30 ml and 56 % for a prostate volume >30 ml, p = 0.002), while their median follow-up of 24 months was relatively short and mean prostate volume was 36.7 ml. In the present study with a median follow-up of 43 months, patients offered NHA and preoperative TURP to reduce the prostatic volume and to resect calcification within the prostate were enrolled into the cohort, and prostate volume at the time of HIFU was a mean of 20.1 ml. Although there was neither significant differences for BFSR when stratified patients according to the administration of NHA nor carrying out of preoperative TURP, we could demonstrate that patients with prostate volume of >20 ml at the time of HIFU had statistically equivalent BFSR compared with prostate volume ≤20 ml. When adequately applied to patients before HIFU, these procedures might have additional benefit for biochemical relapse, clinically leading to excellent treatment outcome. In fact, the 5-year BFSR for Stuttgart definition of 72 % for our cohort including low and intermediate risks appears to beyond the 4-year BFSR of 68 % reported by Pinthus et al.

The PSA nadir value has consistently presented as a major predictive factor for treatment success of HIFU [16, 17]. Similarly, we identified the PSA nadir value as the independent predictor for biochemical failure of Stuttgart definition after single-session HIFU using the Sonablate®. However, concerning that the administration of NHA would affect the nature course of PSA after HIFU has made
those previous studies disinclined to include patients who underwent NHA. Nevertheless, as described previously, we believe that offering NHA is practically essential to reduce prostate volume leading to durable cancer control.

The present study also represented that median time to PSA nadir level after single-session HIFU was 2.5 months allowing an early feedback on treatment efficacy compared with that after EBRT which is usually achieved after 18 months [18, 19]. Additionally, patients who presented a local relapse could be followed by a later using salvage radiation therapy, which might explain the good cancer control after single-session HIFU achieved in 99.4 % of the metastasis-free survival rate and 100 % of CSSR at 5 years. Rebillard et al. [20] reported negative biopsies rate after treatment with the Ablatherm® device reaches 90 % in patients with low- and intermediate-risk disease who underwent routine post-HIFU prostate biopsy. Even though executing rate of follow-up biopsy (60.2 %, 103/171) in our cohort might be relatively low, we could eventually identified 88.3 % (91/103) of patients who presented the threshold PSA level of <1.0 ng/ml at the point of biopsy and revealed 91.2 % (83/91) of negative biopsy rate in those patients, which could have a potential closer to the true treatment outcome than any tracking of biochemical measurements. Crouzet et al. [3] mentioned that the additional treatment survival rate is more accurate to present the real clinical outcomes after HIFU, and the combination of the Phoenix criteria and additional treatment survival, defined as DFSR, represents the real HIFU outcomes, estimating for 72 % in low-, 56 % in intermediate-, and 47 % in high-risk patients. In our findings, the biochemical relapse for low- and intermediate-risk patients seems to be comparable to those previous reports but inferior for high-risk patients while comparing favorably with any risk groups for the DFSR, defined as biochemical relapse for Phoenix definition or positive follow-up biopsy in the present study, including high-risk patients. Interestingly, those previous studies could consider patients experienced new HIFU session as both biochemical- and disease-free. We believe that repeated HIFU treatment might offer the additional benefit in patients with high-risk disease, and the administration of hormone deprivation or EBRT as salvage therapy for the high-risk disease would probably result in the similar DFSR comparing our single-session HIFU treatment outcomes. Moreover, we also believe that HIFU may represent the first step of a multimodal treatment approach in patients with high-risk disease.

**Conclusion**

We firstly assessed the treatment efficacy of single-session HIFU treatment using the Sonablate® for patients with localized prostate cancer. Well-formed application of NHA and preoperative TURP for patients with larger volume and calcification of prostate would induce toward the treatment success where primary HIFU therapy could advance to a new stage the first step among the multimodal treatment including later radiation, radical prostatectomy in patients even with high-risk disease. To verify these findings, further well-designed prospective study is needed.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

1. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123
2. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A (2008) First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 53:1194–1201
3. Crouzet S, Rebillard X, Chevallier D, Rischmann P, Pasticier G, Garcia G, Rouviere O, Chapelon YJ, Gelet A (2010) Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 58:559–566
4. Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A (2011) Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria—analysis from the @-Registry. BJU Int 108:E196–E201
5. Kuban DA, Thomas HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL (2003) Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57:915–928
6. Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Newcastles JC, Robertson CN, Thuroff S, Ward JF (2009) High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 104:1058–1062
7. Roach M 3rd, Hanks G, Thomas H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974
8. Pfeiffer D, Berger J, Gross AJ (2012) Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes. BJU Int 110:1702–1707
9. Pinthus JH, Farrokhyar F, Hassouna MM, Woods E, Whelan K, Shayegan B, Orovan WL (2012) Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology. BJU Int 110:1142–1148
10. D’Amico AV, Whittington R, Malkowicz SB, Schulz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974

 Springer
11. National Comprehensive Cancer Network (2004) Prostate cancer. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2:224–248
12. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035–1041
13. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL (2005) Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 173:797–802
14. Patel A, Dorey F, Franklin J, deKernion JB (1997) Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441–1445
15. Richaud P, Moreau JL, Beuzeboc P, Rebillard X, Villers A, Peyromaure M, Cornud F, Soulie M, Davin JL (2005) Follow-up of prostate cancer. Guidelines of the Comite de Cancerologie de l’Association Francaise d’Urologie. Prog Urol 15:586–592
16. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A (2008) PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 53:547–553
17. Uchida T, Illing RO, Cathcart PJ, Emberton M (2006) To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 98:537–539
18. Morgan PB, Hanlon AL, Horwitz EM, Buuyounouski MK, Uzzo RG, Pollack A (2007) Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer 110:68–80
19. Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE (2009) Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys 75:1350–1356
20. Rebillard X, Soulie M, Chartier-Kastler E, Davin JL, Mignard JP, Moreau JL, Coulange C (2008) High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 101:1205–1213